The Latest Breaking News from Osteoarthritis

Knee injuries are common in athletes, accounting for 41% of all athletic injuries. But knee injuries aren’t limited to competitive athletes. In our everyday lives, an accident or a quick movement in the wrong direction can injure the knee and require medical treatment. A quarter of the adult population worldwide…

The weight-loss jab Wegovy made its debut on June 4 2021. It was the first new weight-loss drug to be approved by the US Food and Drug Administration since 2014.

The drug semaglutide, commonly known by the brand names Ozempic or Wegovy, was originally developed to help people with type 2 diabetes manage their blood sugar levels.

A recent study revealed that semaglutide injections, a drug commonly used for weight loss, could dramatically reduce osteoarthritis symptoms, cutting pain levels by nearly 50%.

The lateral fabella is three times as common today than it was a century ago.

Most people with knee osteoarthritis can control their pain and improve their mobility without surgery, according to updated treatment guidelines from the Australian Commission on Safety and Quality in Health Care.

As the understanding of a common degenerative joint disease shifts, doctors are calling for a rethink of how the condition is treated and discussed.

As you age, your body loses the ability to make sufficient levels of glucosamine needed to maintain cartilage health. Glucosamine sulfate supplements may help improve joint health and mobility.

Tens of thousands of years ago, during a period of Egyptian history known as the Old Kingdom (around 2649–2130 BC), it was rare for people to be able to read and write. From an estimated population of between 1 million and 1.5 million, only about 1% were literate and able…

Given Organogenesis’s (ORGO) upbeat first-quarter results and promising development of its ReNu program for knee osteoarthritis, the company seems to be on the brink of significant growth. Let’s delve into its fundamentals to determine whether it's a hidden gem in the biotech sector. Read more to find out….

The development of osteoarthritis was more common among scribes than their ancient Egyptian peers, a study finds.